Cerebral Diagnostics wins U.S. patent for machine-learning pain diagnosis

Cerebral Diagnostics Canada Inc. says it received a U.S. patent on Sept. 29, 2026 for a system that combines evoked brain responses, signal analysis and machine learning to evaluate pain disorders. The company is positioning the technology as an objective test for fibromyalgia and related conditions, while broader clinical validation and regulatory clearance are still needed.

Why it matters: - Cerebral Diagnostics is targeting one of pain medicine’s hardest problems: measuring pain objectively instead of relying mainly on patient reports. - The patent could strengthen the company’s hand in developing diagnostic tools for fibromyalgia and other disorders where physiological assessment is difficult. - The company is also building a patent portfolio that could support licensing, research partnerships and future medical-device commercialization.

What happened: - Cerebral Diagnostics Canada Inc. received U.S. Patent No. 12,745,947 on Sept. 29, 2026. - The patent is titled “Evaluation of Pain Disorders via Expert System.” - The patent covers combining evoked brain electrical responses, advanced signal analysis and machine learning to diagnose pain disorders. - Patent prosecution was handled by Brian W. Bolinger of Tarolli, Sundheim, Covell & Tummino LLP. - The company announced the patent on Oct. 3, 2026.

The details: - The technology grew out of an effort to build a practical objective test for fibromyalgia. - The platform uses evoked potentials, including somatosensory evoked potentials, to measure electrical responses in the nervous system. - The company records those responses with EEG after an appropriate stimulus is applied. - Pain-related stimuli may include cold, heat, laser, electrical or mechanical stimulation. - In fibromyalgia work, one example uses EEG recordings after pressure is applied to recognized tender points. - The patent describes a category of “mechanical pain disorders.” - The patent family includes applications for fibromyalgia, myofascial pain syndrome, chronic fatigue syndrome, temporomandibular joint disorders, certain forms of back pain, Gulf War Syndrome and Complex Regional Pain Syndrome. - Cerebral Diagnostics says it has developed an initial prototype and completed proof-of-concept work in fibromyalgia. - In an early pilot study, the company says the approach achieved 95% sensitivity in objective diagnosing fibromyalgia from EEG brain signals. - The company says larger studies are needed to establish clinical performance and generalizability. - Additional research, clinical validation and regulatory authorization will be required before the technology can be marketed as a medical diagnostic product. - Cerebral Diagnostics previously patented a robotic arm that repeatedly applies pressure to fibromyalgia tender points to create a standardized stimulus. - Together, the two technologies are intended to create a workflow in which a controlled stimulus is delivered, EEG records the response, signal features are extracted and machine-learning tools identify pain-related patterns. - The company says the same patent family has also received protection in Europe and Japan. - U.S. patent filing - Earlier patent on applying standardized pressure - European patent - Japan patent

Between the lines: - The patent suggests Cerebral Diagnostics is trying to turn EEG-based pain assessment into a broader platform, not a single-disease tool. - The focus on fibromyalgia makes sense because the condition is difficult to confirm with standard objective tests. - The company’s licensing and collaboration pitch signals an effort to turn intellectual property into partnerships before full clinical validation is complete. - Dr. Mark Doidge said the company believes the goal of an objective fibromyalgia test is “well within reach.” - He also said machine learning and signal processing are making EEG more useful for extracting clinically meaningful information from brain waves.

What’s next: - Cerebral Diagnostics says it is looking for academic collaborators, especially fibromyalgia research centers with EEG or machine-learning expertise. - The company is open to licensing talks with medical-device companies, including firms interested in temporomandibular joint disorders. - The company is also seeking military medicine collaborations related to Gulf War Syndrome, back pain and myofascial pain syndrome. - Further studies and regulatory steps will determine whether the technology can move from patent protection to marketable diagnostic products.

The bottom line: - Cerebral Diagnostics has added patent protection around a machine-learning approach to objective pain evaluation, but the business case still depends on larger clinical studies and regulatory clearance.